Ranbaxy Laboratories Limited

Add to watch list to get report alerts
BSE Code: 500359       NSE Code: RANBAXY

Business Profile
Business Profile
Ranbaxy Laboratories manufactures and markets pharmaceutical dosage forms (for human health care), animal health care products, bulk drugs and intermediates, diagnostics, laboratory chemicals and reagents. It is the largest exporter of bulk drugs and pharmaceutical dosage forms in India. Incorporated in 1961, the company went public in 1973.

The company has manufacturing operations in eight countries with a ground presence in 49 countries, and its products are available in over 125 countries. Ranbaxy made an acquisition of RPG Aventis, France which has since been renamed as Ranbaxy Pharmacie Generiques SAS. Laboratorios Ranbaxy was incorporated in Barcelona, Spain as a wholly-owned subsidiary of Ranbaxy Netherlands. Ranbaxy Australia was set up in Sydney as a wholly-owned subsidiary of Ranbaxy Netherlands. ZAO Ranbaxy was incorporated in Moscow, Russia as a wholly-owned subsidiary of Ranbaxy Netherlands. Ranbaxy has Thembalami Pharmaceuticals as its JV. The Group acquired Terapia SA, Ranbaxy Belgium NV, Mundogen Pharma SA, Substantial assets of Allen SpA and Be-Tabs Pharmaceuticals.

The company has decided to lay greater thrust in the areas of novel drug delivery systems and new drug discovery research, enhance emphasis on custom synthesis to draw greater leverage on built-in chemical and clinical research.

The company swung to loss for the quarter ended December 2008. During the quarter, the company reported loss of Rs 8,065.54 million compared with a profit of Rs 484.00 million in the same quarter previous year. Net sales declined marginally 3.90% to Rs 9,546 million, while total income for the quarter fell 9.10% to Rs 10,163.94 million, when compared with the prior year period. It posted loss of Rs 19.63 a share during the quarter compared with earnings of Rs 1.30 a share in previous year period.

Recent Developments
The company has acquired trademarks, product dossiers and marketing rights from Ochoa Laboratories for its entire range of dermatological and ifestyle products.

Basics GmbH (Basics), its German based 100% subsidiary of the company has inked a discount agreement with Germany`s biggest health insurance group, AOK Baden-Wurttemberg to provide generic medicines in Germany.

The company commenced the Phase-III clinical trials for its new anti-malaria combination drug, Arterolanc maleate plus Piperaquine phosphate in India, Bangladesh and Thailand.

The company received an approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), to market and manufacture Topirimate tablets 25mg, 100mg & 200mg.

The company received an approval from the therapeutic goods administration (TGA), Department of Health and Ageing of the Australian Government, for the registration of OZIDAL Risperidone 0.5, 1, 2, 3 and 4 mg tablets in Australia.

The company announced on March 23 that the drug regulatory authorities of the UK and Australia have approved the manufacturing practice followed at the company`s Paonta Sahib plant.

The company has received final approval from the US Food and Drug Administration (USFDA) to market and manufacture Ramipril Capsules in the strengths of 5mg and 10 mg respectively.

The company has received an approval from the Therapeutic Goods Administration (TGA), Department of Health and Ageing, of the Australian Government for the registration of SEBIFIN Terbinafine tablets in Australia.

The company received an approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Quinapril Hydrochloride & Hydrochlorothiazide (Quinapril + HCTZ) tablets, 10 mg/12.5mg, 20mg/12.5mg and 20mg/25mg.

The company received final approval from the US Food and Drug Administration (USFDA) to market Sumatriptan Succinate Tablet, in the strength 100 mg.

The company along with its biggest stakeholder Daiichi Sankyo Company declared the reorganization of board, with CEO & MD Malvinder Mohan Singh assuming the additional responsibility of Chairman.

Leading drug maker, the company has on Wednesday announced that the company had received import permission for marketing of Glidel (polifeprosan 20 with earmustinc implant) Wafer approved by US Food and Drug Administration (USFDA).

The company and Daiichi Sankyo announced the successful closure of their transformational deal with the execution of the final transfer of the remaining equity shares of the Singh family, in Ranbaxy.

Japanese drug major Daiichi Sankyo on October 21, completed its acquisition of a 52.5% equity stake in the company has via off-market and stock exchange transactions, reports Business Standard.

Other Information
Annual Reports for Ranbaxy Laboratories Limited
Annual Report YearDownload Annual ReportDownload Report Preview

Please Note: Clicking on the download link will add the report to your downloaded reports. You will be able to download it at any time during the subscription period.

Free reports will not be deducted from your subscription.

Request a Report
Select Year